Fig. 7

THR-70 improves the identification of ER-negative (ER-) and ER-positive (ER+) subgroups with distinct survival rates compared to the clinical 3-gene classifier and PAM-50. A Kaplan–Meier (KM) survival plots comparing the 20-year recurrence-free survival (RFS) in ER-negative breast cancer groups identified by clinical 3-gene classifier: HER2 + HR = 1.5, 95%CI: 1.1–2.0, p = 0.001 vs. TNBC (left panel); PAM-50 classifier: basal HR = 1.6, 95%CI: 1.2–2.2, p = 0.01 vs. claudin-low (middle panel), and THR-70i: PQNBC.i- HR = 15.7, 95%CI: 8.5–29.0, p < 0.0001 vs. PQNBC.i + (right panel). B KM plots comparing the 20-year RFS in ER + groups identified by clinical 3-gene classifier: ER + HP HR = 1.7, 95%CI: 1.4–2.1, p < 0.0001 vs. ER + LP (left panel), PAM-50: luminal B HR = 1.8, 95%CI: 1.5–2.2, p < 0.0001 vs. Luminal A (middle panel), and THR-70i: E1 HR = 2.1, 95%CI: 1.6–2.7, p <  p < 0.0001; E2 HR = 1.6, 95%CI: 1.3–2.0, p = 0.0001, VS. E3 (right panel). Survival time is in months. The hazard ratios (HR) and 95% confidence intervals (CI) are shown. HP: high proliferation, LP: low proliferation